EP3733713A4 - BISPECIFIC ANTIBODIES AND ITS APPLICATIONS - Google Patents

BISPECIFIC ANTIBODIES AND ITS APPLICATIONS Download PDF

Info

Publication number
EP3733713A4
EP3733713A4 EP19776671.0A EP19776671A EP3733713A4 EP 3733713 A4 EP3733713 A4 EP 3733713A4 EP 19776671 A EP19776671 A EP 19776671A EP 3733713 A4 EP3733713 A4 EP 3733713A4
Authority
EP
European Patent Office
Prior art keywords
applications
bispecific antibodies
bispecific
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19776671.0A
Other languages
German (de)
French (fr)
Other versions
EP3733713A1 (en
Inventor
Wenjun Zhang
Cuijuan CHEN
Xuemei WEI
Tonghui LUO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excelmab Inc
Original Assignee
Excelmab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excelmab Inc filed Critical Excelmab Inc
Publication of EP3733713A1 publication Critical patent/EP3733713A1/en
Publication of EP3733713A4 publication Critical patent/EP3733713A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP19776671.0A 2018-03-27 2019-01-07 BISPECIFIC ANTIBODIES AND ITS APPLICATIONS Pending EP3733713A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810263832.0A CN110305217B (en) 2018-03-27 2018-03-27 Bispecific antibodies and their applications
PCT/CN2019/070655 WO2019184549A1 (en) 2018-03-27 2019-01-07 Bispecific antibody and uses thereof

Publications (2)

Publication Number Publication Date
EP3733713A1 EP3733713A1 (en) 2020-11-04
EP3733713A4 true EP3733713A4 (en) 2021-05-26

Family

ID=68062214

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19776671.0A Pending EP3733713A4 (en) 2018-03-27 2019-01-07 BISPECIFIC ANTIBODIES AND ITS APPLICATIONS

Country Status (7)

Country Link
US (1) US11718671B2 (en)
EP (1) EP3733713A4 (en)
JP (1) JP7066953B2 (en)
CN (1) CN110305217B (en)
AU (1) AU2019240974B2 (en)
CA (1) CA3089254C (en)
WO (1) WO2019184549A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110551221B (en) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 A kind of bispecific antibody and its preparation method and application
KR20220092958A (en) * 2019-11-07 2022-07-04 암젠 인크 High salt wash during cation exchange chromatography to remove product-related impurities
MX2022005593A (en) * 2019-11-07 2022-06-09 Amgen Inc CONDITIONING OF THE CHARGE WITH HIGH SALINITY DURING CATION EXCHANGE CHROMATOGRAPHY TO ELIMINATE RELATED IMPURITIES FROM THE PRODUCT.
CN111748040B (en) * 2020-07-31 2021-09-28 杭州皓阳生物技术有限公司 Multivalent antibodies and methods of making same
JP7853992B2 (en) * 2020-11-10 2026-04-30 上海齊魯制藥研究中心有限公司 Bispecific antibodies against claudin 18A2 and CD3 and their use
CN113527493B (en) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 A B7-H3 antibody and its application
JP2024530166A (en) * 2021-08-04 2024-08-16 アブプロ コーポレーション CD3-Targeting Antibodies and Their Uses
CN115109164A (en) * 2022-06-07 2022-09-27 博际生物医药科技(杭州)有限公司 Bispecific antibodies targeting EPCAM and CD3
US20250011420A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Proteins that bind sp17 including fully-human anti-sp17 antibodies
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
WO2025085781A1 (en) 2023-10-19 2025-04-24 Genentech, Inc. Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055074A2 (en) * 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
WO2015016608A1 (en) * 2013-07-31 2015-02-05 삼성전자 주식회사 Composition for carrying nucleic acid, comprising antibody and nucleic acid-binding peptide
CN104829728A (en) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 Construction and application of bispecific antibody HER2*CD3

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935531B2 (en) 2000-02-22 2011-05-03 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
EP2181595A1 (en) 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
KR101131727B1 (en) 2004-06-11 2012-03-28 가톨릭대학교 산학협력단 DENDRITE CELLS TRANSDUCED WITH RECOMBINANT ADENOVIRUS AdVCEA WHICH GENERATE CEA-SPECIFIC CYTOTOXIC T LYMPHOCYTES, VACCINE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
JP5686953B2 (en) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー Compositions comprising cross-species-specific antibodies and uses of the compositions
DK1989224T3 (en) 2006-02-24 2011-02-14 Us Gov Health & Human Serv Immunogenic peptides and methods of use
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008127285A2 (en) 2006-10-05 2008-10-23 The Board Of Trustees Of The University Of Arkansas Target peptides for ovarian cancer immunotherapy
CA2682605A1 (en) * 2007-04-18 2008-10-30 Zymogenetics, Inc. Single chain fc, methods of making and methods of treatment
HUE029925T2 (en) * 2008-04-02 2017-04-28 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
WO2015063339A1 (en) * 2013-11-04 2015-05-07 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
MX379030B (en) * 2013-12-17 2025-03-10 Genentech Inc Anti-cd3 antibodies and methods of use
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
CN104558192B (en) * 2015-01-21 2018-12-28 武汉友芝友生物制药有限公司 A kind of building and application of bispecific antibody HER2XCD3
WO2016014974A2 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
KR102095096B1 (en) * 2015-08-26 2020-03-30 바이슨 테라퓨틱스 인크. Multispecific antibody platforms and related methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009055074A2 (en) * 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
WO2015016608A1 (en) * 2013-07-31 2015-02-05 삼성전자 주식회사 Composition for carrying nucleic acid, comprising antibody and nucleic acid-binding peptide
CN104829728A (en) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 Construction and application of bispecific antibody HER2*CD3

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019184549A1 *
WUELLNER ULRICH ET AL: "Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity", ANTIBODIES, vol. 4, no. 4, 8 December 2015 (2015-12-08), pages 426 - 440, XP055795432, DOI: 10.3390/antib4040426 *

Also Published As

Publication number Publication date
JP2021511052A (en) 2021-05-06
EP3733713A1 (en) 2020-11-04
AU2019240974B2 (en) 2022-12-01
CN110305217A (en) 2019-10-08
US20210122823A1 (en) 2021-04-29
CN110305217B (en) 2022-03-29
US11718671B2 (en) 2023-08-08
JP7066953B2 (en) 2022-05-16
CA3089254A1 (en) 2019-10-03
AU2019240974A1 (en) 2020-08-13
WO2019184549A1 (en) 2019-10-03
CA3089254C (en) 2025-06-10

Similar Documents

Publication Publication Date Title
FR25C1029I2 (en) Bispecific anti-BCMA-X anti-CD3 antibodies and their uses
EP3838289A4 (en) ANTI-TIGIT ANTIBODIES AND ITS USES
EP3762030A4 (en) ANTI-CD73 ANTIBODIES AND ASSOCIATED USES
EP4261231A4 (en) BISPECIFIC ANTIBODY AND CORRESPONDING APPLICATION
MA52742A (en) BISPECIFIC ANTIBODIES DLL3-CD3
EP3897719A4 (en) PROTEASE-CLEATABLE BISPECIFIC ANTIBODIES AND USES THEREOF
EP3626825A4 (en) ANTI-CDH6 ANTIBODY AND ANTI-CDH6 ANTIBODY CONJUGATE-DRUG
PT3802608T (en) ANTI-CD3 ANTIBODIES AND THEIR USES
EP3473649A4 (en) ANTI-CD47 MONOCLONAL ANTIBODIES AND CORRESPONDING APPLICATION
IL289354A (en) Anti-154cd antibodies and their uses
EP3587453A4 (en) ANTI-PD-L1 ANTIBODIES AND ITS APPLICATION
EP3411071A4 (en) NOVEL MONOCLONAL ANTIBODIES ANTI-CD 47 AND USES THEREOF
MA50505A (en) 2 + 1 BISPECIFIC ANTIBODIES (CONTORSBODIES)
EP3999545A4 (en) ANTI-CD73 ANTIBODIES AND ITS APPLICATION
PL3383916T3 (en) ANTI-CD73 ANTIBODIES AND THEIR APPLICATIONS
EP3604338A4 (en) ANTI-OX40 ANTIBODIES AND CORRESPONDING USE
EP3621642A4 (en) HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES
EP3589660A4 (en) ANTI-PD-L1 ANTIBODIES AND RELATED USES
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
EP3400243A4 (en) ANTI-PD-L1 ANTIBODIES AND USES THEREOF
MA43955A (en) BISPECIFIC ANTI-BCMA AND ANTI-CD3 BITE-FORMAT ANTIBODIES
EP3575318A4 (en) ANTI-PD-1 ANTIBODIES AND ITS USE
EP3883967A4 (en) ANTI-CD38 AND ANTI-ICAM1 ANTIBODIES AND THEIR USES
EP3684812A4 (en) ANTI-CTLA4 ANTIBODIES AND ASSOCIATED USES
EP3356416A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20210423

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101AFI20210419BHEP

Ipc: C07K 16/28 20060101ALI20210419BHEP

Ipc: C07K 16/46 20060101ALI20210419BHEP

Ipc: C12N 15/85 20060101ALI20210419BHEP

Ipc: A61K 39/395 20060101ALI20210419BHEP

Ipc: A61K 47/68 20170101ALI20210419BHEP

Ipc: A61P 35/00 20060101ALI20210419BHEP

Ipc: C07K 16/32 20060101ALI20210419BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210720